Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman AA.

AAPS J. 2013 Apr;15(2):316-23. doi: 10.1208/s12248-012-9439-1. Epub 2012 Dec 11.

2.
3.

Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.

Othman AA, Chatamra K, Mohamed ME, Dutta S, Benesh J, Yanagawa M, Nagai M.

Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.

4.
5.
6.

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA.

Parkinsonism Relat Disord. 2013 Mar;19(3):339-45. doi: 10.1016/j.parkreldis.2012.11.020. Epub 2013 Jan 1.

7.

Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.

Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L.

Acta Neurol Scand. 2013 May;127(5):e28-32. doi: 10.1111/ane.12075. Epub 2013 Jan 11.

PMID:
23311399
8.

Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.

Antonini A, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators.

Parkinsonism Relat Disord. 2015 Mar;21(3):231-5. doi: 10.1016/j.parkreldis.2014.12.012. Epub 2014 Dec 19.

9.

Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.

Bohlega S, Abou Al-Shaar H, Alkhairallah T, Al-Ajlan F, Hasan N, Alkahtani K.

Eur Neurol. 2015;74(5-6):227-36. doi: 10.1159/000442151. Epub 2015 Dec 1.

PMID:
26618531
10.

Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.

Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS.

Parkinsonism Relat Disord. 2015 Jul;21(7):742-8. doi: 10.1016/j.parkreldis.2015.04.022. Epub 2015 Apr 28.

11.

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.

Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM.

Clin Neuropharmacol. 2003 May-Jun;26(3):156-63.

PMID:
12782919
12.

Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.

Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L.

Eur J Neurol. 2014 Feb;21(2):312-8. doi: 10.1111/ene.12309. Epub 2013 Dec 7.

13.

The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.

Băjenaru O, Ene A, Popescu BO, Szász JA, Sabău M, Mureşan DF, Perju-Dumbrava L, Popescu CD, Constantinescu A, Buraga I, Simu M.

J Neural Transm (Vienna). 2016 Apr;123(4):407-14. doi: 10.1007/s00702-015-1496-z. Epub 2015 Dec 23.

14.

Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.

Jost WH.

Expert Opin Drug Saf. 2014 Apr;13(4):447-58. doi: 10.1517/14740338.2014.896336. Epub 2014 Mar 10. Review.

PMID:
24611456
15.

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.

Vaz-da-Silva M, Loureiro AI, Nunes T, Lopes C, Rocha J, Machado R, Costa R, Torrão L, Falcão A, Wright L, Almeida L, Soares-da-Silva P.

Drugs R D. 2008;9(6):435-46. doi: 10.2165/0126839-200809060-00006.

PMID:
18989992
16.

[Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].

Skoromets AA, Odinak MM, Yakupov EZ, Litvinenko IV, Zalyalova ZA, Timofeeva AA, Kirtaev SY, Bogdanov RR, Agafina AS, Chatamra K, Robieson W, Benesh J, Latypova GR, Ershova MV, Illarioshkin SN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2):22-31. doi: 10.17116/jnevro20171172122-31. Russian.

PMID:
28374689
17.

Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.

Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS.

J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.

PMID:
26777085
18.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group.

Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum in: Lancet Neurol. 2014 Mar;13(3):240.

19.

[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].

Toth A, Nagy H, Wacha J, Bereczki D, Takáts A.

Neuropsychopharmacol Hung. 2015 Dec;17(4):191-6. Review. Hungarian.

20.

Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.

Müller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F.

J Neural Transm (Vienna). 2011 Sep;118(9):1329-33. doi: 10.1007/s00702-011-0614-9. Epub 2011 Feb 27.

PMID:
21359971

Supplemental Content

Support Center